The Inflation Reduction Act includes drug price negotiation as a key component. Whether drugs were selected for negotiation in 2023 or will be chosen in the future, their impact will be significant, especially in therapeutic areas affected by negotiation. Manufacturers are proactively assessing risk and preparing for the margin impact resulting from negotiation.
James Brown
Vice President, U.S. Market Access Strategy Consulting, IQVIA
Rob Glik
Vice President and GM, Value & Access Strategy Consulting, IQVIA
Data, AI, and expertise empower Commercial Solutions to optimize strategy, accelerate market access, and maximize brand performance.
Gain high value access and increase the profitability of your brands
